Tocilizumab Access and Patient Education Shape Outpatient Bispecific Therapy

In an interview with Pharmacy Times, Manale Maksour, PharmD, BCOP, BCPS, associate director of Pharmacy Services at American Oncology Network, discussed payer barriers involving tocilizumab and the importance of patient and caregiver education during outpatient bispecific therapy.

Maksour explained that payers generally approve bispecific therapies for outpatient administration without significant difficulty. Tocilizumab, however, can present a greater reimbursement challenge, particularly when it is used prophylactically to reduce the risk or severity of cytokine release syndrome (CRS). Although coverage is typically less problematic when tocilizumab is administered to treat an active episode of CRS, some payers may resist approving the medication before symptoms develop.

These denials can directly affect treatment planning. Maksour noted that some physicians may not feel comfortable proceeding with outpatient step-up dosing for certain patients without prophylactic tocilizumab. In those cases, the care team may appeal the payer’s decision, administer the bispecific therapy without prophylaxis when clinically appropriate, or refer the patient to a hospital for inpatient treatment. Maksour emphasized that covering prophylactic tocilizumab may ultimately help avoid the greater costs associated with severe CRS and hospitalization.

Patient and caregiver education is equally critical to the success of outpatient treatment. Patients must understand that bispecific therapy is not comparable to a routine chemotherapy visit in which treatment is administered and the patient immediately returns home without additional monitoring. During the initial step-up doses, patients may remain in the clinic for extended observation and must continue monitoring themselves after leaving.

Patients and caregivers should know how to check temperature, blood pressure, and heart rate, as well as recognize possible symptoms of CRS and immune effector cell–associated neurotoxicity syndrome, including fever, headache, and confusion. They must also understand when to contact the clinical team or seek emergency care.

Although the first weeks can be demanding, Maksour explained that treatment generally becomes more routine as the risk of acute toxicities decreases. With appropriate education, preparation, and support, outpatient bispecific therapy can provide an effective treatment option for a growing number of patients.